Efficacy of macrolides used in combination with ethambutol, with or without other drugs, against Mycobacterium avium within human macrophages

Int J Antimicrob Agents. 2001 Dec;18(6):525-30. doi: 10.1016/s0924-8579(01)00461-7.

Abstract

The activities of clarithromycin or roxithromicin used in combination with other antimicrobial drugs were tested in human macrophages experimentally infected with 23 strains of Mycobacterium avium. Overall, clarithromycin-ethambutol-rifampicin was the most active combination tested. The reduction in intracellular viable bacilli was found to be more than 1 log(10) for 95% and more than 2 logs(10) for 65% of the strains. The second most active combination was roxithromycin-ethambutol-rifampicin, which was found to be bactericidal for about 80% and highly bactericidal for 20% of the strains. Others combinations were only bacteriostatic or weakly bactericidal for many of the strains. The addition of a third drug did not necessarily promote enhanced bacterial killing inside the macrophage.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Antitubercular Agents / pharmacology*
  • Cells, Cultured
  • Clarithromycin / pharmacology
  • Drug Therapy, Combination / pharmacology*
  • Ethambutol / pharmacology*
  • Humans
  • Macrophages / microbiology*
  • Microbial Sensitivity Tests
  • Mycobacterium avium / drug effects*
  • Mycobacterium avium / growth & development
  • Rifampin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Antitubercular Agents
  • Ethambutol
  • Clarithromycin
  • Rifampin